EUVIMEDEUVIMED entdecken
Crossref

Comparative Evaluation of High-Flow Nasal Cannula Oxygen Therapy and Non-Invasive Ventilation in COPD Patients with Acute Hypercapnic Respiratory Failure

Hariprasath K, S. Rishabh, Laxman N

International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)

DOI: 10.25258/ijcpr.18.5.237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Hariprasath K und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute hypercapnic respiratory failure is a common complication of acute exacerbations of chronic obstructive pulmonary disease (COPD). Non-invasive ventilation (NIV) is the recommended first-line therapy; however, high-flow nasal cannula (HFNC) oxygen therapy has emerged as a potential alternative with improved patient tolerance. This study aimed to compare the clinical effectiveness, physiological outcomes, and patient tolerance of HFNC and NIV in COPD patients with acute hypercapnic respiratory failure.

Methods

This prospective comparative study included 203 patients with COPD presenting with acute hypercapnic respiratory failure. Patients received either HFNC (n = 101) or NIV (n = 102) as respiratory support. Baseline demographic characteristics, physiological parameters, and arterial blood gas values were recorded. Changes in arterial blood gas parameters at 24 hours, clinical outcomes, device-related complications, and predictors of treatment failure were analyzed.

Results

Both HFNC and NIV significantly improved arterial blood gas parameters after treatment. NIV demonstrated a greater improvement in arterial pH and a larger reduction in PaCO₂ at 24 hours compared with HFNC (p < 0.01). The need for endotracheal intubation was significantly higher in the HFNC group (17.8%) than in the NIV group (9.8%) (p = 0.009). Patient comfort scores were significantly higher with HFNC (7.8 ± 1.3 vs 6.2 ± 1.7; p < 0.001), and device-related complications such as skin breakdown and gastric distension were more common with NIV. Multivariate analysis identified baseline pH 70 mmHg, and respiratory rate >32/min as independent predictors of treatment failure.

Conclusion

Both HFNC and NIV improve gas exchange in COPD patients with acute hypercapnic respiratory failure. NIV provides greater reduction in hypercapnia and lowers the risk of intubation, whereas HFNC offers better patient comfort and tolerance. NIV should remain the preferred first-line therapy, while HFNC may be considered in selected patients, particularly those unable to tolerate NIV.

Zitieren

APA

K, H., Rishabh, S., & N, L. (2026). Comparative Evaluation of High-Flow Nasal Cannula Oxygen Therapy and Non-Invasive Ventilation in COPD Patients with Acute Hypercapnic Respiratory Failure. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.237

Vancouver

K H, Rishabh S, N L. Comparative Evaluation of High-Flow Nasal Cannula Oxygen Therapy and Non-Invasive Ventilation in COPD Patients with Acute Hypercapnic Respiratory Failure. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.237

BibTeX
@article{K2026,
  author = {K, Hariprasath and Rishabh, S. and N, Laxman},
  title = {Comparative Evaluation of High-Flow Nasal Cannula Oxygen Therapy and Non-Invasive Ventilation in COPD Patients with Acute Hypercapnic Respiratory Failure},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {05},
  doi = {10.25258/ijcpr.18.5.237}
}
Kostenlos starten →